Status:
COMPLETED
Natural Killer (NK) Cell Transplantation for AML
Lead Sponsor:
St. Jude Children's Research Hospital
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
Up to 21 years
Phase:
NA
Brief Summary
The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced ...
Detailed Description
Natural killer (NK) cells extracted from a \[parental\] donor are infused intravenously. Most patients are given a multi-agent chemotherapeutic conditioning regimen prior to the infusion. The conditio...
Eligibility Criteria
Inclusion
- Participants with AML that is in complete remission, is relapsed or refractory, or with increasing minimal residual disease.
- Participants in complete remission must have recovered from toxicity of previous therapy and have evidence of bone marrow recovery
- Participants who had prior stem cell transplant (SCT) must have no evidence of GVHD and 60 or more days have elapsed since the SCT.
Exclusion
- Participants who are pregnant
- Participants with inadequate renal, liver, or pulmonary functions
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00187096
Start Date
September 1 2005
End Date
March 1 2013
Last Update
June 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105